Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | PDE2A | O00408 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16447038 | 0.97 | TSHR (0.57) | TSHRPDE2AACHETDP1CA1 | |
| Iodide SCHEMBL25233686 | 0.97 | TSHR (0.57) | TSHRPDE2AACHETDP1CA1 | |
| SCHEMBL11624060 | 0.88 | PDE2A (0.48) | TSHRPDE2AACHETDP1CA1 | |
| SCHEMBL1706121 | 0.87 | PDE2A (0.62) | TSHRPDE2ATDP1AKT1AKT2 | |
| SCHEMBL19523658 | 0.82 | NFE2L2 (0.43) | TSHRPDE2ACA1MAPTCYP1A2 | |
| SCHEMBL2892242 | 0.82 | TSHR (0.60) | TSHRPDE2AACHETDP1CA1 | |
| SCHEMBL10843149 | 0.82 | TSHR (0.60) | TSHRPDE2AACHETDP1CA1 | |
| SCHEMBL15745695 | 0.82 | TSHR (0.60) | TSHRPDE2AACHETDP1CA1 | |
| SCHEMBL6049865 | 0.81 | TSHR (0.58) | TSHRACHETDP1CA1CA2 | |
| SCHEMBL3667462 | 0.80 | TSHR (0.50) | TSHRPDE2AACHETDP1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-56131553-A | — | — | None | — | — | JP | disclosed |
| US-20260007688-A1 | SYNTHETIC ANALOGS OF CANNABINOL (CBN) FOR THE TREATMENT OF AGERELATED NEUROLOGICAL DISORDERS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2024258789-A1 | MODULATORS OF CDK2 AND USES THEREOF | TRIANA BIOMEDICINES, INC. (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024148193-A1 | SYNTHETIC ANALOGS OF CANNABINOL (CBN) FOR THE TREATMENT OF AGE-RELATED NEUROLOGICAL DISORDERS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | ARBUTUS BIOPHARMA CORP (CA) | 2023-10-05 | — | — | US | disclosed |
| WO-2023154282-A1 | COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2023-05-25 | — | — | US | disclosed |
| EP-4008758-A2 | ORGANOMETALLIC COMPOUND, LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING LIGHT-EMITTING DEVICE | Samsung Display Co., Ltd. (KR) | 2022-06-08 | — | — | EP | disclosed |
| US-10442693-B2 | Porous nanostructured polyimide networks and methods of manufacture | AEROGEL TECHNOLOGIES, LLC (US) | 2019-10-15 | — | — | US | disclosed |
| EP-0635485-B1 | TETRAHYDROPHTHALAMIDE DERIVATIVE, INTERMEDIATE FOR PRODUCING THE SAME, PRODUCTION OF BOTH, AND HERBICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT | SAGAMI CHEM RES (JP) | 1997-06-11 | — | — | EP | disclosed |
| US-5554581-A | Tetrahydrophthalamide derivative, intermediate for producing the same, production of both, and herbicide containing the same as active ingredient | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0725074-A2 | Compounds suitable for use as intermediates in the preparation of Androst-3,5-dien-3-carboxy derivatives | SANKYO COMPANY LIMITED (JP) | 1996-08-07 | — | — | EP | disclosed |
| US-5536714-A | Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-16 | — | — | US | disclosed |
| US-5506190-A | Tetrahydrophthalamide derivative, intermediate for producing the same, production of both, and herbicide containing the same as active ingredient | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0635485-A1 | TETRAHYDROPHTHALAMIDE DERIVATIVE, INTERMEDIATE FOR PRODUCING THE SAME, PRODUCTION OF BOTH, AND HERBICIDE CONTAINING THE SAME AS ACTIVE INGREDIENT | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1995-01-25 | — | — | EP | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| US-4627874-A | RICE PRODUCTION | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1986-12-09 | — | — | US | disclosed |
| US-4455164-A | HALOGENATED DERIVATIVES | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1984-06-19 | — | — | US | disclosed |
| JP-S56131553-A | OPTICALLY ACTIVE N-BENZYL-HALOACETAMIDE DERIVATIVE, ITS PREPARATION, AND HERBICIDE CONTAINING SAID DERIVATIVE AS EFFECTIVE COMPONENT | SUMITOMO CHEM CO LTD | 1981-10-15 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007688-A1 | SYNTHETIC ANALOGS OF CANNABINOL (CBN) FOR THE TREATMENT OF AGERELATED NEUROLOGICAL DISORDERS | AIFM2, FECH, NLN | TSHR 2061/4885PDE2A 4557/4885ACHE 2187/4885 |
| US-20230312481-A1 | SUBSTITUTED (PHTHALAZIN-1-YLMETHYL)UREAS, SUBSTITUTED N-(PHTHALAZIN-1-YLMETHYL)AMIDES, AND ANALOGUES THEREOF | NSD3, PML, NSD1 | TSHR 3398/4885PDE2A 3619/4885ACHE 4527/4885 |
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | ENPP1, ENPP3, PPA1 | TSHR 3987/4885PDE2A 932/4885ACHE 1513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.